Home
Questo sito è destinato ai professionisti sanitari.

Paradigmi in evoluzione nel carcinoma polmonare: Modulo 2 – Razionale delle terapie con anticorpi bispecifici PD-(L)1 × VEGF

Condividi

Descrizione

Questa attività è supportata da un contributo educazionale indipendente della BioNTech-BMS Alliance. Questo programma di formazione online è stato ideato per i professionisti sanitari a livello globale.

Unisciti al Dott. Joshua Sabari mentre esplora il ruolo emergente degli anticorpi bispecifici PD-(L)1 × VEGF nel tumore al polmone. Attraverso una revisione dei loro meccanismi d'azione unici e delle più recenti evidenze cliniche, questo modulo di microlearning guidato da esperti esamina come queste nuove terapie possano superare i limiti degli attuali approcci terapeutici e plasmare la futura gestione del NSCLC e del SCLC.

Preferisci leggere? Leggi qui la nostra Sintesi Clinica Principale.

Punti Salienti della Sessione

  • Esplorare la scienza alla base degli anticorpi bispecifici PD-(L)1 × VEGF, inclusi i loro meccanismi d'azione e come si differenziano dalle terapie con anticorpi monoclonali convenzionali.
  • Esaminare le più recenti evidenze cliniche per gli agenti bispecifici emergenti, tra cui ivonescimab e pumitamig, nel NSCLC e nel SCLC.
  • Interpretare i risultati chiave dei recenti studi clinici, inclusi gli studi Harmony e Rosetta Lung, e le loro potenziali implicazioni per la futura pratica clinica.
  • Comprendere la direzione futura del trattamento del tumore al polmone, compresi gli studi di Fase III in corso e il ruolo in evoluzione degli anticorpi bispecifici nel migliorare gli esiti per i pazienti.

Pubblico di Riferimento

Questa attività è rivolta a oncologi medici, pneumologi, infermieri specializzati, assistenti medici, farmacisti, infermieri e altri professionisti sanitari che si occupano della cura dei pazienti con tumore al polmone, inclusi il tumore del polmone non a piccole cellule (NSCLC) e il tumore del polmone a piccole cellule (SCLC).

Corpo Docente

Il Dott. Joshua Sabari è un oncologo medico toracico presso il Perlmutter Cancer Center della NYU Langone Health, specializzato nel trattamento del tumore del polmone non a piccole cellule e a piccole cellule. La sua pratica clinica si concentra sull'offerta di cure personalizzate e centrate sul paziente, mentre la sua ricerca è dedicata allo sviluppo di terapie guidate da biomarcatori e al progresso della medicina di precisione attraverso studi clinici innovativi. È impegnato a tradurre le evidenze emergenti in approcci pratici che migliorino gli esiti per i pazienti con tumore al polmone.

Dichiarazioni sui Conflitti di Interesse (Disclosures)

In conformità con le linee guida EBAC®, tutti i relatori e moderatori che partecipano a questo programma hanno dichiarato o indicato eventuali potenziali conflitti di interesse che potrebbero influenzare le loro presentazioni. Il Comitato Organizzatore/Direttore del Corso è responsabile di garantire che tutti i potenziali conflitti di interesse rilevanti per l'evento siano resi noti al pubblico prima dell'inizio delle attività di formazione continua.

Il Dott. Joshua Sabari, docente per questa attività, ha dichiarato i seguenti rapporti finanziari negli ultimi 36 mesi con le seguenti aziende non idonee (ineligible companies):

Consulente, Advisor, Relatore: AbbVie, AstraZeneca, Boehringer Ingelheim, EMD Serono, Genentech, Janssen (Johnson & Johnson), Jazz, Loxo Lilly, Mirati/Bristol Myers Squibb, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, Takeda.

Ricerca: Boehringer Ingelheim, Janssen (Johnson & Johnson), Loxo Lilly, Mirati/Bristol Myers Squibb, Regeneron.

Il personale MedAll, così come i pianificatori e i revisori, non hanno rapporti finanziari rilevanti con aziende non idonee da dichiarare.

Informazioni ECM (CME) EBAC®

Questa attività è stata pianificata e implementata in conformità con i requisiti e le politiche di accreditamento dell'European Board for Accreditation of Continuing Education for Health Professionals (EBAC).

MedAll è un provider accreditato EBAC dal 2025. L'European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredita i programmi di Formazione Continua (CE) per la comunità medica internazionale.

Questo programma è accreditato dall'European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) per 15 minuti di tempo di formazione effettivo.

In conformità con le linee guida EBAC, tutti i relatori/presidenti che partecipano a questo programma hanno dichiarato o indicato potenziali conflitti di interesse che potrebbero causare distorsioni (bias) nelle presentazioni. Il Comitato Organizzatore/Direttore del Corso è responsabile di garantire che tutti i potenziali conflitti di interesse rilevanti per l'evento siano dichiarati al pubblico prima delle attività di CE.

L'EBAC® ha stipulato un accordo di mutuo riconoscimento di equivalenza sostanziale con l'US Accreditation Council for CME (ACCME) e il Royal College of Physicians and Surgeons of Canada, rispettivamente.

Tramite un accordo tra l'European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) e l'American Medical Association (AMA), i medici possono convertire i crediti CME esterni EBAC® in crediti AMA PRA Category 1. Le informazioni sulla procedura per convertire i crediti EBAC® in crediti AMA sono disponibili sul sito web dell'AMA. Altri professionisti sanitari possono ottenere dall'AMA un certificato di partecipazione a un'attività idonea per la conversione del credito in crediti AMA PRA Category 1.

L'Accreditation Council for Continuing Medical Education (ACCME) e il Royal College of Physicians and Surgeons of Canada hanno un accordo di equivalenza sostanziale dei sistemi di accreditamento con l'EBAC.

L'EBAC® è membro dell'International Academy for CPD Accreditation (IACPDA) e membro partner dell'International Association of Medical Regulatory Authorities (IAMRA).

Come ottenere i crediti CME EBAC®

Per ottenere il credito CME e ricevere il certificato, si prega di partecipare all'attività e completare la valutazione al termine. Si riceverà un link al certificato dopo aver completato la valutazione.

Costi di Partecipazione e Dettagli

La partecipazione a questo programma è gratuita.

Questa attività di formazione continua è attiva a partire dal 22 luglio 2026 e scadrà il 14 luglio 2027.

Tempo stimato per il completamento di questa attività: 15 Minuti.

Community simili

Visualizza tutto

Eventi e video on-demand simili

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

My name is Josh Sabari. I'm a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York. Really excited to discuss evolving paradigms in lung cancer, clinical integration of PD1 and PDL1 VEGF bi-specific monoclonal antibodies. These are my disclosures. In the discussion today, we're gonna define by specific antibodies, a really hot and exciting area in lung cancer, as well as all solid tumors. We'll talk about the background, the innovation, the mechanism of action of these agents. We'll also talk about the development strategy in lung cancer. And I wanna Spotlight or highlight two novel therapies here, Ivanesimab, a PD1 VEGF monoclonal antibody, as well as pumidomi, a PDL1 VEGFA, uh, monoclonal antibody or bi-specific antibody in this setting. And then we'll end, uh, with some conclusions. So for the objective one of the discussion, we're gonna talk about the mechanism of action shift, and you'll sort of get where I'm going. We're moving from single monoclonal antibodies to more bi-specific. Why? We know that bi-specific antibodies may improve specificity as well as reduce the Rates of, um, you know, resistance and recurrence of disease. So we'll look at PD1 and PDL1, VEGF by specific antibody therapies. How do they differ from conventional therapy and how may they improve patient outcomes? We'll look at exciting data presented recently at ASCO 2026. So we know that monoclonal antibodies were designed to recognize one epitope or antigen. Here you can see a monoclonal antibody uh with two arms targeting that same antigen. We'll say antigen A binding site. When we think about bi-specific antibodies, we're, we're constructing, we're engineering these antibodies to be able to target multiple epitopes. Here we're looking at two. And the idea being that we may be able to improve specificity, and we may be able to target multiple different, you know, sort of redundancies or, or inconsistencies or liabilities in the tumor as well in, as in our immune system. So when I think about a bi-specific antibody, again, it's targeting two different epitopes or antigens, and these really range in size. Size from small proteins to large IgG-like molecules with additional domains, and you can imagine for a bi-specific antibody, you know, the, the, the sky is the limit. We can really build upon this platform for thinking about different strategies. Today, we're gonna focus on PD1, VEGF, but you can think about different constructs that can exist and they're being developed in the clinic now. Now, it's important to think about the physical linkage of two binding specificities that can create a dependency both across time and across space. And I think it's a little bit out there, but we know that binding events temporarily can occur sequentially, and we know that spatially, they can occur simultaneously. And this can lead to, again, enhanced activity of these agents in The clinical practice setting. And we have a few of these already FDA approved for use in solid tumor oncology. So Amiantumab and EGFR and met bi-specific antibody, FDA approved for the management of EGFR mutant non-small cell lung cancer. We recently saw the approval of tarlatumab, a CD3, uh, DLL-3 bi-specific, uh, um, uh, monoclonal antibody. B-specific antibody. And, you know, tarlatumab being unique in that it's targeting CD3, uh, which is expressed on T cells. So this is a bite or a bi-specific T cell engager. And also recently, we saw the approval of xenoctuzumab, a HER2, HER3 bi-specific antibody, uh, FDA approved an NRG1 fusion-positive metastatic non-small cell lung cancer. So, a lot of work has gone into developing these bio-specific antibodies. And if you look at the literature, early literature from the 1960s first mentions this idea of, you know, sort of scientifically fiction. Could we create antibodies that target more than one thing? And a lot of work has been done, both targeting FC portion of the receptor, uh, um, to try to better understand and how to, you know, sort of manipulate these. Constructs to better achieve our outcome, which is targeting uh tumor cells and also targeting the tumor microenvironment. So again, the first bi-specific monoclonal antibody that was approved in lung cancer dates back to about 2021, uh, 2022 now with Amivanumab, uh, in EGFR mutant metastatic non-small cell lung cancer, and we've seen so many more, uh, developed over the last, uh, couple of years. So, what is the mechanism of action here? Well, we know that there's a multi-modality mechanism of action. So there's many ways that these bi-specific antibodies are targeting. Uh, they can be bridging cells, uh, to the affector cell. Uh, we can see sort of receptor directly inhibiting. We can also see receptor activation if it's occurring in cysts. And then also, you can see sort of direct inhibition and downstream signaling prevention. Um, another thing that can occur is if you're engaging immune cells. Here I'm showing the ADCC or antibody-dependent cellular cytotoxicity. You can see this is a bite looking at a T cell, CD3 engaging, and on the tumor cell here, potentially engaging. CLL 3, you can see that you can actually get immune activation. And this occurs actually with all our uh bi-specific monoclonal antibodies, including PD1 uh and uh PDL1 VEGF bi-specific antibodies in the clinical practice setting. So what is the mechanism of action specifically now looking at a PD1 VEGF by specific? Well, again, we know a lot about VEGF inhibition, vascular endothelial growth factor. We know that tumors can secrete VEGFA and that promotes neovascularization, leading to growth and invasion and metastasis. Multiple therapeutic modalities have been developed to target um VEEGF, and we know that by inhibiting VEGF, we can Starve tumor cells by blocking tumors, nutrient and oxygen supply. So there are monoclonal antibodies such as bevacizumab, for example, or ramisumumab, both FDA approved and non-small cell lung cancer that have shown progression-free survival as well as overall survival benefit. We also have multikinase inhibitors um that target VEGF that are approved outside of lung cancer but being developed as well in the lung cancer setting. I don't have to explain to you PD1 or PDL1. You all know well, uh, that there's an explosion of immune checkpoint inhibitors approved. We know that PD1 is expressed on immune cells, T cells in particular, uh, and it's an inhibitory receptor. Whereas PDL1 is expressed on tumor cells and really acts as the ligand, and this system of binding prevents autoimmunity and allows for immune evasion. Uh, so preventing the immune system. From recognizing and attacking things that it shouldn't be attacking. And here, uh, tumor cells, which we would hope the immune system would potentially, uh, recognize as foreign. So by, by co-opting this system, by using a checkpoint inhibitor, PD1 or PDL1 inhibitor, we can activate, uh, um, this uh system to allow uh T cell activation and, uh, autoimmunity, which is again, uh, something that we are co-opting in this population. Now, why do we need them to be specifically a bi-specific, right? Why can't we just use a PD1 or a PDL1 inhibitor with a VEGF inhibitor simultaneously? Well, we know that the presence of VEGF increases PD1 and PDL1 binding avidity. By 17, 18-fold in some studies. And we also know that the presence of PD1 and PDL1 increases VEGF binding avidity. So these, these uh binding actually will improve specificity of these agents in this setting. So there's been an explosion of data. Here, we'll start with Ivanesimab, uh, a PD1, uh, VEGF, a bi-specific antibody. We saw data from the Harmony A trial, uh, which was done, uh, in EGFR mutant non-small cell lung cancer in the second line. There is also a Harmony study, which is the global study of this, uh, looking at Ivanesimab plus chemotherapy versus chemotherapy alone. And we did see a preliminary improvement in over Overall survival as well as progression-free survival. This is currently sitting with the FDA for approval. Harmony Two was also done in China. This is in the first-line driver mutation negative space in non-small cell lung cancer. And we studied Ivanesimab here versus pembrolizumab in those patients with PDL1 greater than 1%. We looked at both non-small cell squam as well as non-squam. And one can argue that pembrolizumab is a Single agent is the wrong control arm for patients with PDL1 less than 50%. Median progression-free survival was positive, 11 months versus about 6 months, and median overall survival not yet reached. More recently, we saw data at ASCO 2026 on the Harmony Six trial, which looked at first-line squamous patients receiving Ivanesimab plus chemo versus tisillizumab, a PDI1. Inhibitor plus chemotherapy. Very nicely designed trial, again, done in China only here. Positive for progression-free survival, but was also very impressive, positive for median overall survival, 28 months for the treatment arm versus 24 months for the control arm. Again, this is China-only data. They did not enroll patients greater than 75 years, and they excluded patients with particular risk factors like hemoptysis, for example.